Digital repository of Slovenian research organisations

Show document
A+ | A- | SLO | ENG

Title:Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer : an observational study
Authors:Hochmair, Maximilian J (Author)
Morabito, Alessandro (Author)
Hao, Desiree (Author)
Yang, Cheng-Ta (Author)
Soo, Ross A (Author)
Yang, James C-H (Author)
Gucalp, Rasim (Author)
Halmos, Balazs (Author)
Wang, Lara (Author)
Golembesky, Amanda (Author)
Märten, Angela (Author)
Čufer, Tanja (Author)
Tipology:1.01 - Original Scientific Article
Organisation:Logo UKPBAG - University Clinic of Respiratory and Allergic Diseases Golnik
Abstract:Aim: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting. Materials & methods: In this retrospective, observational, multicenter study, patients (n = 204) had T790M-positive disease following first-line afatinib and started osimertinib treatment [>/=]10 months prior to data entry. Primary outcome was time on treatment. Results: Overall median time on treatment was 27.6 months (90% CI: 25.9-31.3), 30.3 months (90% CI: 27.6-44.5) in Del19-positive patients and 46.7 months (90% CI: 26.8-not reached) in Asians. The 2-year overall survival was 78.9%. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib facilitates prolonged, chemotherapy-free treatment in patients with T790M acquired resistance, and is a potentially attractive strategy, especially for Del19-positive tumors.
Keywords:lung neoplasms -- therapy, non-small-cell lung cancer, afatinib, osimertinib, epidermal growth factor receptor, EGFR, observational study
Year of publishing:2018
Publisher:Future Medicine Ltd
Source:Velika Britanija
COBISS_ID:2048432753 Link is opened in a new window
ISSN on article:1744-8301
OceCobissID:521824025 Link is opened in a new window
DOI:10.2217/fon-2018-0711 Link is opened in a new window
Note:Soavtorji: Alessandro Morabito, Desiree Hao, Cheng-Ta Yang, Ross A Soo, James C-H Yang, Rasim Gucalp, Balazs Halmos, Lara Wang, Amanda Golembesky, Angela Märten & Tanja Cufer; Nasl. z nasl. zaslona; Opis vira z dne 9. 1. 2019;
Files:.pdf PDF - Presentation file, download (2,39 MB)
URL URL - Source URL, visit
Journal:Future oncology
Future Medicine
Rights:2018 Maximilian Hochmair
Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.


License:CC BY-NC-ND 4.0, Creative Commons Attribution Non-Commercial No Derivatives 4.0 International
Description:The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.
Licensing start date:19.10.2018